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Summary. Background and aim of the work: Radiofrequency ablation (RFA) is the gold standard for the treat-
ment of symptomatic osteoid osteoma (OO) as RFA yields both a high success and low complication rate. It 
has been widely utilized over the years, but recurrences of OO after this treatment have been documented. 
These recurrences may be the result of various factors, including incomplete tumor ablation, and are signifi-
cantly higher in lesions greater than 10 mm. Thus, the need to induce thermal ablation in a wider area led us to 
use a Multi-Tined Expandable Electrode System (MTEES). In this study we examined the efficacy and safety 
of RFA using a MTEES in symptomatic OO. Methods: Between January 2005 and June 2007, 16 patients 
with symptomatic OO were treated by CT-guided percutaneous RFA using a MTEES. The diameter of OO 
ranged from 6 to 15 mm (mean 10±2.6 mm). Patients were evaluated for clinical outcomes, complications and 
recurrence. Pain evaluation was assessed preoperatively, 2 weeks postoperatively and at last follow-up. Results: 
Clinical follow-up was available for all patients at a mean of 84.3 months (range 73-96 months). Mean pre-
operative VAS score was 7.4 (range 5-9), two weeks after the procedure mean VAS score was 0.3 (range 0-1) 
with a mean change of -7.06 points (p<0.0001). At the last follow-up a complete relief from pain has been 
observed in all patients. No major and minor complications were observed nor recurrences. Conclusions: RFA 
using a MTEES has been effective, safe and reliable for the treatment of OOs. This system, by increasing the 
size of the necrosis, could be a viable alternative to the single needle electrode in lesions larger than 10 mm, 
reducing the risk of recurrence.  (www.actabiomedica.it)
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Introduction
Osteoid osteoma (OO) is a small, benign, osteo-
blastic lesion that appears primarily in young patients 
(1-3). Even though OO is a benign lesion, surgical 
treatment may be necessary if pain is persistent.
In the past, open “en bloc” surgical excision has 
been considered the gold standard for treatment of OO 
with an overall success of 88% (4-6). Disadvantages of 
open surgical procedure include a large bone and soft 
tissue damage (3). Furthermore, wider resection of the 
lesion may cause a bone defect that becomes a zone 
of lower mechanical resistance which, if subjected to 
stresses early, may create a fracture (7).
In the last two decades, percutaneous CT-guided 
procedures have been developed for the treatment of 
OO’s. Some authors reported percutaneous drill resec-
tion with a success rate similar to the open techniques, 
from 84% to 100% (8-10). However, this technique is 
associated with a high number of complications, up to 
24%, represented mainly by fractures and infections 
(7).
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Currently, radiofrequency ablation (RFA) is the 
gold standard in the treatment of OO with high suc-
cess and low complication rates. The active electrode 
needle tip is able to induce thermal coagulative necro-
sis of the lesion through a controlled increase of the 
temperature (11-13).
Recurrence rate of the lesion, after open or per-
cutaneous surgery, is related to the presence of residual 
areas of nidus. In RFA, the main risk factor for recur-
rence is the non-optimal positioning of the electrode 
needle and larger OO’s. In lesions greater than 10 mm 
reposition of the electrode needle and multiple abla-
tions are recommended to reduce the risk of recurrence 
(14-16).
The need to induce thermal ablation in a wider 
area, especially in lesions larger than 10 mm, led us 
to use a multi-tined expandable electrode system 
(MTEES). It consists of a central straight-needle can-
nula that is used to deploy an array of curved electrode 
tines from the tip to the adjacent tissue, which allows a 
wider coagulative necrosis of the lesion.  
Objective
The aim of this retrospective study is to examine 
the efficacy and safety of RFA using a MTEES in pa-
tients with symptomatic OO.
Methods
Between January 2005 and June 2007, 16 patients 
(10M, 6F) with symptomatic OO’s were treated by 
CT-guided percutaneous RFA using a MTEES. The 
average age at surgery was 19 ± 3.3 years (range 14-26 
years). We detected 10 lesions in the femur (62.5%) 
and 6 (37.5%) in the tibia. The side mostly affected 
was the left (10 cases). The mean duration of pain be-
fore the procedure was 12.5 ± 5.3 months (range 6-24 
months). Medical records of patients were analyzed 
retrospectively after ethics committee approval. No 
histological diagnosis has been performed in our pa-
tients due to the typical clinical and radiological find-
ings. The distance from skin to the bone ranged from 
4.1 cm to 8.3 cm (mean 6.5 cm, SD 1.8 cm). The di-
ameter of OO ranged from 6 to 15 mm (mean 10 ± 
2.6 mm): size greater than 15 mm was considered as 
exclusion criteria.
As inclusion criteria, we selected patients with a 
minimum distance of the bone lesion from the skin 
over 4 cm to prevent the risk of cutaneous and thermal 
lesions. Patients data is described in Table 1.
All patients had mainly nocturnal pain with posi-
tive temporary response to NSAIDs. Plain radiography 
and computed tomography (CT) scan showed a central 
radiolucent nidus surrounded by reactive bone sclerosis.
The procedures were performed using CT (So-
matom Plus 64, Siemens Medical Solutions, Forch-
heim, Germany) under general anesthesia. 
To perform RFA we used the RITA system 
(RITA Medical Systems, Mountain View, Califor-
nia, USA) composed of a radiofrequency monopolar 
generator 150-200W (Rita 1500 X, AngioDynamics 
Incorporated) and a needle electrode 14G with nine 
expandable active hooks and five thermocouples (mo-
nopolar Rita Starburst XL). The needle electrode al-
lows controlled release of nine metal hooks that rep-
resent the active part that transmits energy. The tines 
are deployed and retracted with a simple helical rota-
tion of the hub. Thermocouples placed at the tips of 
five prongs of the nine-array needle-electrode enabled 
continuous real-time monitoring of the actual temper-
atures at the tips. When deployed, the tines function 
as antennae, expanding and concentrating the current 
density and predictably enlarging the lesion.
Before the proce dure, prothrombin time and in-
ternational normalized ratio values were checked. In 
addition, whole blood count, allergy and anesthesia 
status were evaluated. All patient received preoperative 
short-term antibiotic prophylaxis with Cefamezin 2 g.
A CT scan was performed to localize the lesion 
and identify the optimal entry point.  Two adhesive 
grounding pads were placed on the patient. A sterile 
field was prepared with povidone-iodine (10%) solu-
tion. A 2.2-mm Kirschner wire was inserted into the 
center nidus and then advanced and anchored about 
an inch and a half deeply in the bone (Fig. 1a). A 2 
cm skin incision and release adjacent soft tissue were 
performed at the K-wire entry point in order to ease 
the insertion of a 5 mm cannulated drill with the K-
wire as a guide (Fig. 1b). Once verified the position of 
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the cannulated drill on the k-wire and the contact with 
the bone, a 5-mm diameter hole was drilled through 
the nidus using an electrical orthopedic drill under 
CT-guidance to create an optimal cavity to receive the 
multi-tined expandable electrode (Fig. 1c). After the 
removal of cannulated drill and k-wire, the dispersive 
pads were connected to the generator to close the cir-
cuit and disperse the heat. The multi-tined expandable 
electrode was placed in its closed configuration at the 
center of the previously drilled hole (Fig. 1d). Once 
connected to the radiofrequency generator, the elec-
trode tines were deployed for about 1-1.5 cm to deliver 
energy to a wide area of bone lesion (Fig. 1e). 
A CT scan was obtained to verify the optimal 
placement of the electrodes. Afterwards, thermal ab-
lation was performed with a target temperature of 
90°C for 4-6 minutes.  A laptop computer was used 
to graphically display, in real time, the curves of the 
temperatures at the tips, the power of the generator, 
and the impedance of the tissues over time. Once a rise 
in impedance was achieved and the thermal ablation 
ended, a final CT scan was performed.
We evaluated the clinical and perioperative course 
using medical records and patient labels. We ana-
lyzed preoperative, intraoperative and postoperative 
CT scans. Clinical evaluation was performed using 
a pain visual analogue scale (VAS) from 0 (no pain) 
to 10 (unbearable pain), considering a pain between 
7 and 10 as severe, between 5 and 6 as moderate, and 
between 0 and 4 as slight. Pain was assessed preop-
eratively, 2 weeks postoperatively and at the time of 
the last follow-up. Complications were classified into 
major and minor according to the recommendations 
of the Society of Interventional Radiology (17-18). 
We defined recurrence as the persistence or return of 
symptoms after a remission.
Results were evaluated in terms of pain reduction 
or absence of pain. The difference between pre and 
postoperative pain was evaluated with paired T-test. 
Significance was set at a P value less than or equal to 
0.05.
Results
All patients were available with an average fol-
low-up of 84.3 ± 7.7 months (range 73-96 months). 
The results are described in Table 2.
Table 1. Clinical data
Patient Age (yrs) Gender Side Location Size (mm) Duration of pain (mo) FU* (mo)
1 15 M Right Femur 11 12 74
2 18 M Right Femur 9 7 80
3 16 F Right Tibia 6 9 86
4 22 M Left Tibia 8 6 90
5 19 F Right Femur 11 8 75
6 14 F Left Femur 9 9 96
7 18 M Left Femur 7 11 94
8 22 M Left Tibia 13 20 90
9 26 M Left Tibia 12 9 88
10 24 M Left Femur 7 24 80
11 20 F Left Femur 10 15 73
12 22 M Right Femur 11 16 81
13 18 M Right Tibia 8 12 78
14 17 M Left Femur 14 20 94
15 18 F Left Femur 15 14 79
16 20 F Left Tibia 12 8 91
Minimum 14 M:10 Left:10 Femur: 10 6 6 73
Maximum 26 F:6 Right:6 Tibia: 6 15 24 96
Average 19.3    10.2 12.5 84.3
SD ** 3.3    2.6 5.3 7.7
* FU: follow up; ** SD: standard deviation
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Figure 1. a) A 2.2-mm Kirschner wire inserted into the center 
nidus; b) Insertion of a 5-mm cannulated drill using the K-wire 
as a guide; c) Drilling of the cortical bone over the nidus; d) 
Insertion of the multi-tined expandable electrode in its closed 
configuration into the lesion; e) RF ablation of the lesion using 
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The procedure was technically feasible in all pa-
tients. The mean operative time from induction of an-
esthesia was 65.5 ± 11.5 minutes (range 48-90 min-
utes). The clinical results according to VAS are sum-
marized in Table 2: VAS pain scores improved at all 
postoperative time points. Mean preoperative pain 
score was 7.4±1.1 (range 5-9), two weeks after the 
procedure mean pain score was 0.3 (range 0-1) with 
a mean change of 7.06 points (p<0.0001). At the last 
follow-up all patients reported a VAS score of 0. The 
percentage of clinical success was 100%. We did not 
observe any recurrence. No major and minor compli-
cations were observed.
Discussion
The satisfactory clinical results reported in our 
retrospective study confirm the efficacy of RFA in the 
treatment of OO, as widely reported in the interna-
tional literature (12, 13, 19). In our study, RFA using 
a MTEES was completed successfully in all patients. 
Furthermore, in all cases we achieved complete remis-
sion of symptoms, without any recurrence of pain at 
last follow-up.
Several studies on RFA have shown a high safety 
with a complication rate as low as 3% (12, 13, 15, 20-
22). RFA complications are mostly due to cutaneous 
and thermal burns in the zone of approach (23-25). In 
this regard, attention should be given in the presence 
of superficial OOs, in which the distance between the 
skin and the bone is minimal, to avoid the risk of creat-
ing burns from thermal necrosis (24, 26-29). Some au-
thors also recommend using extra care when treating 
OOs located less than 10 mm from nerve or vascular 
structures (25, 30). In our study, there were no ma-
jor or minor complications in intra and postoperative 
phases. Due to the device design, we choose to select 
patients in which the minimum distance of the bone 
lesion from the skin was over 4 cm to prevent the risk 
of cutaneous and thermal burns and allow an appropri-
ate expansion of the hooks.
None of our patients had a histological diagnosis. 
The main disadvantage of percutaneous RFA is indeed 
Table 2. Procedure data and clinical results
Patient Procedure  Bone-skin Major Minor VAS* VAS* VAS* Recurrence FU**
 time distance complication complication preop 14 days FU  (mo)
 (min) (mm)    postop
1 65 80 None None 7 0 0 No 74 
2 48 71 None None 8 1 0 No 80 
3 62 42 None None 7 0 0 No 86 
4 55 45 None None 9 1 0 No 90 
5 70 80 None None 7 1 0 No 75 
6 65 78 None None 6 0 0 No 96 
7 72 81 None None 8 0 0 No 94 
8 80 34 None None 6 0 0 No 90 
9 70 41 None None 5 0 0 No 88 
10 80 72 None None 8 0 0 No 80 
11 50 78 None None 8 1 0 No 73 
12 55 83 None None 7 0 0 No 81 
13 68 58 None None 7 0 0 No 78 
14 90 68 None None 8 1 0 No 94 
15 60 66 None None 9 0 0 No 79 
16 58 68 None None 8 0 0 No 91 
Minimum 48 41   5 0   73 
Maximum 90 83   9 1   96 
Average 65.5 65   7.4 0.3   84.3 
SD** 11.5 18   1.1 0.47   7.7 
*VAS: Visual analogue scale; **FU: follow up
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the inability to get histological confirmation: the biop-
sy material is often poor in quality and quantity. Many 
authors argue that the histological diagnosis of OO 
before RFA is not needed due to the typical presenta-
tion (20), however, others prefer to take a sample of 
tissue before treatment (31). Furthermore, in case of 
treatment failure or relapse a histopathological confir-
mation may be needed (31).
Recurrence of pain after RFA is the result of in-
complete tumor ablation (32). Some authors reported a 
recurrence rate variable from 0 to 35% (14-16, 28, 33). 
Kjar and co-workers reported that the recurrence rate 
is significantly higher in OOs with a diameter greater 
than 10 mm (16). In lesions greater than 10 mm repo-
sition of the electrode needle and multiple ablations 
are recommended to reduce the risk of recurrence (14-
16). In our study, we achieved clinical success without 
recurrence, even in those cases (7 patients) with a le-
sion larger than 10 mm. Because of our findings, we 
concur that the MTEES increases the volume of tissue 
heated, producing a larger ablation zone compared to 
a standard monopolar cannula.
Two protocols of RFA for the treatment of OO 
are usually reported in the literature: 4 minutes at 90°C 
(12, 13, 23, 24) or 6 minutes at 80°C (34). In our study, 
we successfully applied a thermal ablation time of 4-6 
minutes at 90°C.  Moreover, real-time monitoring of 
the temperatures recorded on thermocouples, placed 
at the tips of the prongs of this system, and rise in 
impedance of the tissues over time proved to be effec-
tive in controlling the temperature reached during the 
procedure and in predicting a successful ablation (35).
Conclusions
RFA using a MTEES has proven to be effective, 
safe and reliable for the treatment of OOs. We did not 
report any recurrences despite the presence of a high 
number of patients with lesions greater than 10 mm. 
Expandable metal tines allowed to diffuse the RF cur-
rent density in the target tissue thereby increasing the 
functional electrode surface area and the size of the 
necrosis. This device could be a viable alternative to 
the single needle electrode in the case of larger OOs, 
reducing the risk of recurrence. However, expandable 
needle systems are not suitable for OOs located su-
perficially. Therefore, we recommend its use in lesions 
at least 4 cm deep, to allow an appropriate expansion 
of the tines and reduce the risk of skin burns. Further 
studies related to the use of this device in larger popu-
lations of patients are needed for proving its advantage 
over other currently available RFA systems.
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